---
company: Syra Health Corp
ticker: SYRA
form: 8-K
filed: 2026-08-11
accession: 0001493152-26-036995
source: https://www.sec.gov/Archives/edgar/data/1922335/000149315226036995/
---

# Syra Health (SYRA) earnings release, August 11, 2026

Syra Health Corp (SYRA) · Form 8-K, Item 2.02 · Filed 2026-08-11 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1922335/000149315226036995/)

Syra

Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter

Carmel,

Ind., August 11, 2026 /

PRNewswire – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the second quarter ended June 30, 2026.

Q2

2026 Financial Highlights

Syra

Health continued to be profitable in Q2 2026, with net income of $250,242 compared to a net loss of $(63,596) in the prior-year period, an improvement of approximately $314,000 or 493% year-over-year.

Total revenue of $2.4 million for the quarter ended June 30, 2026, was up 23% when compared to $1.9 million in the prior-year period.

Revenue growth outpaced cost growth in Q2 2026, resulting in gross margin expansion of approximately 584 basis points to 44.5%, up from 38.7% in the prior-year period, the highest quarterly gross margin in the Company’s history.

EPS improved to $0.02 from a loss of $(0.01) in the prior-year period, reflecting a $0.03 per share year-over-year improvement.

EBITDA increased by $307,000 year-over-year, improving from a loss of $(53,760) in Q2 2025 to positive EBITDA of $253,200 in Q2 2026.

For the six months ended June 30, 2026, net income was $491,221 compared to a net loss of $(535,861) in the prior-year period, and net cash provided by operating activities was $643,183 compared to $85,754 in the prior-year period.

2026

Financial Outlook

Following two consecutive profitable quarters, Syra Health remains focused on achieving its previously stated target of full-year profitability for 2026. Certain revenue recognition, timing, and contract milestones are expected to continue to contribute to quarterly variability.

Recent

Operational Highlights

Syra

Health received contract extensions from several existing customers, including a one-year renewal of its public health contract with

Wake County Public Health in North Carolina. The Company also secured a one-year extension of its healthcare workforce contract with the Indiana Veterans’ Home. The Company has been awarded an amendment to its existing Indiana FSSA (Family & Social Services

Administration) contract with DDRS (Division of Disability and Rehabilitative Services), to extend a learning management platform to the state’s Bureau of Disability Services, through October 2028.

Syra

Health has established a Business Advisory Council to support strategic market expansion and identify growth opportunities.

The

Company anticipates approval for the CMS ACCESS Model in partnership with HealthSync in the near term, which is expected to serve as a durable source of revenue for Syra Health over the next 10 years.

Management

Commentary

Greg

Alexander, CEO of Syra Health, said, “Q2 2026 represents another important milestone in Syra Health’s evolution as we continue to execute against our growth strategy to build a leading, sustainable healthcare solutions company. Following our first ever profitable quarter in Q1, we achieved continued profitability in Q2, grew revenue by 23% year-over-year, and expanded our gross margin to 44.5%, demonstrating the strength of our business model and the impact of our focus on operational efficiency, disciplined growth, and higher-value solutions.

We are encouraged by the continued momentum across our business, including growth in our population health solutions, contract extensions with existing customers, progress toward CMS ACCESS Model approval, and continued demand for our healthcare workforce solutions. These achievements reflect the confidence our customers place in Syra Health and our ability to address some of healthcare’s most pressing challenges around access, affordability, and outcomes.

As we look ahead, we remain focused on sustaining full-year profitability, while continuing to grow our customer base and deliver innovative solutions that improve health outcomes. We believe our diversified portfolio, technology-enabled solutions, and strong market partnerships position Syra Health for continued long-term growth and value creation for our shareholders.”

Q2

2026 Financial Results

Revenue for the second quarter of 2026 grew to $2.4 million, an increase of 23% when compared to $1.9 million in the second quarter of 2025.

Growth was led by the Company’s high-margin population health solutions, which grew 8% year-over-year to $1,716,310 million from

$1,583,752 million in Q2 2025.

Healthcare workforce revenue increased 87% year-over-year, from $362,447 to $678,113 as demand for our healthcare workforce solutions grew to address critical workforce shortages and the Company continued to focus on better margin contracts.

Gross profit margin expanded 580 basis points to 44.5% in the second quarter of 2026, compared with 38.7% in the prior year period, reflecting revenue mix and continued operating leverage.

Operating expenses reflected continued cost management, while allowing for strategic spending to support growth. Salaries and benefits increased

20% to $392,136 in Q2 2026 from $326,354 in the prior-year period, reflecting investments in talent to support business expansion. Professional services decreased 16% to $138,019 in Q2 2026 from $164,939 in Q2 2025, while selling, general and administrative expenses also declined

18% to $236,485 compared with $289,070 in the prior-year period. Research and development expenses increased 59% to $47,351 in Q2 2026 from $29,712 in Q2 2025, reflecting allocations in our technology-enabled solutions. Depreciation expense decreased 88% to $741 from

$5,978 in the year-ago period.

Net cash provided by operating activities for the six months ended June 30, 2026, was $643,183, compared to $85,754 in the prior-year period.... (truncated)2.1 million as of June 30, 2026, compared to $2.9 million as of March 31, 2026, and $1.6 million as of

December 31, 2025, reflecting a $552,000 increase in accounts receivable and the recognition of deferred revenue that had been billed in advance during the first quarter.

Cash on hand was $2.1 million and no long-term debt as of June 30, 2026.

SYRA

HEALTH CORP.

BALANCE

SHEETS

SYRA

HEALTH CORP.

STATEMENTS

OF OPERATIONS

(Unaudited)

SYRA

HEALTH CORP.

STATEMENTS

OF CASH FLOWS

(Unaudited)

Non-GAAP

Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America (“GAAP”), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

About

Syra Health

Syra

Health is an integrated healthcare solutions company serving government and commercial healthcare organizations with innovative solutions designed to improve health outcomes. We specialize in healthcare prevention, expanding access, and delivering affordable solutions. Our healthcare analytics capabilities provide proactive, actionable insights and data-driven intelligence, and our HIPAA-compliant and fully accessible digital health solutions enable measurable health outcomes in highly regulated healthcare environments. Through training and education, we help healthcare organizations reduce costs and deliver consistent, high-quality care.

Discover our healthcare solutions at www.syrahealth.com and follow the Company on

LinkedIn.

Forward-Looking

Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”

“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact

Christine

Drury

IR/PR

Director

Syra

Health christined@syrahealth.com

463-345-5180

## Financial statements

### Income Statement (For the Three Months Ended — (Unaudited))

| | For the Three Months Ended – 2026 | For the Three Months Ended – 2025 | For the Six Months Ended – 2026 | For the Six Months Ended – 2025 |
|---|---:|---:|---:|---:|
| Net revenues | 2,394,423 | 1,946,199 | 4,667,943 | 3,803,973 |
| Cost of services | 1,328,120 | 1,193,304 | 2,630,385 | 2,461,922 |
| Gross profit | 1,066,303 | 752,895 | 2,037,558 | 1,342,051 |
| Operating expenses: | Salaries and benefits | 392,136 | 326,354 | 764,245 | 833,561 |
| Operating expenses: | Professional services | 138,019 | 164,939 | 325,160 | 388,965 |
| Operating expenses: | Research and development expenses | 47,351 | 29,712 | 54,272 | 66,885 |
| Operating expenses: | Selling, general and administrative expenses | 236,485 | 289,070 | 449,532 | 576,357 |
| Operating expenses: | Depreciation | 741 | 5,978 | 1,795 | 12,775 |
| Operating expenses: | Total operating expenses | 814,732 | 816,053 | 1,595,004 | 1,878,543 |
| Operating expenses: | Operating income (loss) | 251,571 | -63,158 | 442,554 | -536,492 |
| Other income (expense): | Interest income | 888 | 3,420 | 53,346 | 7,718 |
| Other income (expense): | Interest expense | -2,217 | -3,858 | -4,679 | -7,087 |
| Other income (expense): | Total other income (expense) | -1,329 | -438 | 48,667 | 631 |
| Other income (expense): | Net income (loss) | 250,242 | -63,596 | 491,221 | -535,861 |
| Other income (expense): | Weighted average common shares outstanding - basic | 13,175,433 | 11,939,169 | 12,560,716 | 11,764,086 |
| Other income (expense): | Weighted average common shares outstanding - diluted | 13,551,931 | 11,939,169 | 12,937,216 | 11,764,086 |
| Other income (expense): | Net income (loss) per common share - basic and diluted | 0.02 | -0.01 | 0.04 | -0.05 |

### Income Statement (Six Months Ended)

| | Six Months Ended – June 30, 2026 | Six Months Ended – June 30, 2025 |
|---|---:|---:|
| Net Income (Loss) | 491,221 | -535,861 |
| Interest expense | 4,679 | 7,087 |
| Depreciation expense | 1,795 | 12,775 |
| Earnings before Interest, Taxes Depreciation and Amortization | 497,695 | -515,999 |

### Income Statement (Three Months Ended)

| | Three Months Ended – June 30, 2026 | Three Months Ended – June 30, 2025 |
|---|---:|---:|
| Net Income (Loss) | 250,242 | -63,596 |
| Interest expense | 2,217 | 3,858 |
| Depreciation expense | 741 | 5,978 |
| Earnings before Interest, Taxes Depreciation and Amortization | 253,200 | -53,760 |

### Balance Sheet (December 31, — BALANCE SHEETS)

| | June 30, – 2026 – (Unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 2,123,747 | 1,614,733 |
| Current assets: | Accounts receivable, net | 1,470,023 | 918,374 |
| Current assets: | Other current assets | 153,384 | 205,423 |
| Current assets: | Total current assets | 3,747,154 | 2,738,530 |
| Current assets: | Property and equipment, net | 5,192 | 6,986 |
| Current assets: | Right-of-use asset | 77,644 | 27,401 |
| Current assets: | Total assets | 3,829,990 | 2,772,917 |
| Current liabilities: | Accounts payable | 195,595 | 247,520 |
| Current liabilities: | Accounts payable, related party | 125,000 | 72,000 |
| Current liabilities: | Accrued expenses | 220,333 | 194,821 |
| Current liabilities: | Deferred revenue | 505,886 | 16,611 |
| Current liabilities: | Current portion of operating lease liability, related party | 77,644 | 27,401 |
| Current liabilities: | Notes payable | 71,694 | 116,386 |
| Current liabilities: | Total current liabilities | 1,196,152 | 674,739 |
| Current liabilities: | Total liabilities | 1,196,152 | 674,739 |
| Stockholders’ equity: | Class A common stock, $0.001 par value, 100,000,000 shares authorized, 13,839,169 and 11,339,169 shares issued and outstanding, respectively | 13,839 | 11,339 |
| Stockholders’ equity: | Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 350,000 and 600,000 shares issued and outstanding, respectively | 350 | 600 |
| Stockholders’ equity: | Additional paid-in capital | 11,848,954 | 11,806,765 |
| Stockholders’ equity: | Accumulated deficit | -9,229,305 | -9,720,526 |
| Stockholders’ equity: | Total stockholders’ equity | 2,633,838 | 2,098,178 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 3,829,990 | 2,772,917 |

### Cash Flow (For the Six Months Ended — (Unaudited))

| | For the Six Months Ended – June 30, – 2026 | For the Six Months Ended – June 30, – 2025 |
|---|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net income (loss) | 491,221 | -535,861 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Depreciation | 1,795 | 12,775 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Common stock issued for services |  | 2,586 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Stock-based compensation | 44,439 | 54,067 |
| Changes in operating assets and liabilities: | Accounts receivable | -551,649 | -205,534 |
| Changes in operating assets and liabilities: | Other current assets | 141,516 | 157,985 |
| Changes in operating assets and liabilities: | Right-of-use asset | 29,877 | 277,029 |
| Changes in operating assets and liabilities: | Accounts payable | -51,926 | 455,366 |
| Changes in operating assets and liabilities: | Accounts payable, related party | 53,000 |  |
| Changes in operating assets and liabilities: | Deferred revenue | 489,275 | 250,000 |
| Changes in operating assets and liabilities: | Accrued expenses | 25,512 | -105,630 |
| Changes in operating assets and liabilities: | Operating lease liability | -29,877 | -277,029 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 643,183 | 85,754 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Proceeds from sale of common stock and exercise of warrants |  | 14,800 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Repayments on notes payable | -134,169 | -190,035 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Net cash used in financing activities | -134,169 | -175,235 |
| CASH FLOWS FROM FINANCING ACTIVITIES | NET CHANGE IN CASH AND CASH EQUIVALENTS | 509,014 | -89,481 |
